An interventional study of Regulated cannabis access in pharmacies in Cannabis Use Disorder, Mental Health Disorder and Physical Illness, sponsored by Health Department of the Canton of Basel-Stadt. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Health Department of the Canton of Basel-Stadt · Not applicable, Interventional, and Other
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.
2,107 studies on the registry are indexed under Mental Disorders; 416 are open to participants now.
This study's enrollment of 374 is above the median of 94 across 1,574 interventional studies indexed under Mental Disorders.
Browse Mental Disorders studies →This is the only study on the registry with Health Department of the Canton of Basel-Stadt as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Immediately regulated cannabis access in pharmacies.
Other: Regulated cannabis access in pharmacies
During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access.
The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
Change in problematic cannabis consumption behaviour
Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Change in depression
Patient Health Questionnaire; min. value 0, max. value 27; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Change in anxiety
Generalized Anxiety Disorder; min. value 0, max. value 21; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30months
Change in psychosis
Checklist of early intervention; min. value 0, max. value 8; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Change in physical health
Symptom Checklist - 90, Somatization; min. value 0, max. value 48; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Plan to share: Yes — All IPD that underlie results in publications.
Supporting information: Sap, Icf
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.